Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 11Terminated 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Cirrhosis 1Carcinoma, Hepatocellular 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 10tislelizumab 9apatinib 9regorafenib 6camrelizumab 6donafenib 5atezolizumab 5Immune Checkpoint Inhibitors 4Hepatectomy 4cabozantinib 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2durvalumab 2anlotinib 2Surgical Procedures, Operative 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × Erlotinib Hydrochloride × Clear all
NCT04172779 2026-05-01

ECHO-B

University of Texas Southwestern Medical Center

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡